Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Delivering ECMO-BIOMARKER – a ground-breaking ICT-enabled ECMO Biomarker system providing clinicians with bedside decision support for better care and reduced costs of severe ICU patients

Project description

A diagnostic tool for oxygenation treatment of ICU patients

Patients with acute respiratory failure whose lung function is lower than 20 % require an external machine to oxygenate their blood, a treatment known as extracorporeal membrane oxygenation (ECMO). However, diagnosis is based on rudimentary tools, which often leads to unnecessary ECMO treatment. The EU-funded ECMO-BIOMARKER project is in the process of developing a novel diagnostic tool for severe lung injury patients that relies on clinical biomarkers. Using novel algorithms, researchers will develop a predictive model for delivering accurate ECMO diagnosis recommendations for each patient in less than two minutes. The tool is expected to cut ICU costs and improve the quality of care of patients.

Objective

One out of ten ICU respiratory patients are characterised as being “severe”, with a lung function of less than 20% due to acute respiratory failure. This group are often referred to ECMO (Extra Corporal Membrane Oxygenation) treatment, in which the patient’s blood is oxygenized by an external machine, costing European healthcare centres €26Bn+ annually. The problem is, due to the rudimentary tools that ICU doctors use to diagnose these patients, 20% of all ECMO patients should not have been treated with ECMO and instead could have stayed in conventional intensive ventilation care. Industry partner Mermaid Care aims to solve this problem with ECMO-BIOMARKER – the world’s first biomarker-based companion diagnostic tool for severe lung injury patients. ECMO-BIOMARKER will potentially reduce ECMO referrals by 10-20%, slashing costs for the average European ECMO centre by an estimated €23-48M annually. Based on clinically predictive biomarker measurements, ECMO-BIOMARKER uses novel algorithms and physiological model to deliver accurate diagnosis recommendations for each patient, bedside and in less than 2 minutes. This ICT-approach changes workflow and empowers low-skilled ICU doctors to perform ECMO diagnosis. In the proposed action, ECMO-BIOMARKER value proposition (reduction in ECMO patients) will be clinically documented together with 4 world-leading partners in the field of ICU management and ECMO treatment: 3 clinical research partners – Imperial College London with the clinical site Royal Brompton Hospital (UK), Medical University of Vienna (AT) and Centre Hospitalier Universitaire de Clermont-Ferrand (FR) – and research partner Aalborg University (DK). After the project, ECMO-BIOMARKER is launched on the EU market, allowing European hospitals to cut ICU costs and improve patient quality of care. This project will allow Mermaid Care to reach sales of €160M in 2025 and hire 30 new employees. The innovation is based on +16 years of research and 10 patents.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

IA - Innovation action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-FTI-2018-2020

See all projects funded under this call

Coordinator

MERMAID CARE AS
Net EU contribution
€ 1 651 475,00
Address
HEDELUND 1
9400 Norresundby
Denmark
SME
Yes
Region
Danmark Nordjylland Nordjylland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 359 250,00

Participants (4)